Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price target is Yen4,800.00.

Koichi Mamegano has given his Buy rating due to a combination of factors surrounding Takeda Pharmaceutical Co. The company has demonstrated strong financial performance in the third quarter, with revenue and core operating profit meeting expectations. Despite some underperformance in Entyvio sales, the overall results were positive, aided by a less-than-expected impact from the Vyvanse patent expiration. Additionally, Takeda raised its full-year earnings forecast and announced a significant share buyback program, which highlights management’s confidence in the company’s future growth.
Another reason behind the Buy rating is the strategic changes within the company, including the planned succession of the CEO position. The appointment of Julie Kim, who has extensive experience and familiarity with Takeda’s operations, is expected to be favourably received. Furthermore, the company’s pipeline remains robust, with upcoming Phase 3 results for several treatments potentially serving as catalysts for future growth. These aspects collectively underpin the positive outlook for Takeda, justifying the Buy rating.

Takeda Pharmaceutical Co (TKPHF) Company Description:

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.